<DOC>
	<DOCNO>NCT01684969</DOCNO>
	<brief_summary>This blind study compare absorption topical haloperidol placebo</brief_summary>
	<brief_title>Evidence Haloperidol Absorption After Topical Administration</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<criteria>Inclusion Criteria Age : patient must 18 year old less 70 year age . Provision inform consent No previous adverse reaction haloperidol No current use haloperidol Good health No alcohol within 24 hour study No significant cardiovascular , gastrointestinal , hematologic , neurologic , renal , hepatic pulmonary disease . Normal neurologic exam Exclusionary Criteria Evidence significant clinical disorder laboratory find make undesirable patient participate study Recent cerebral trauma Study exclude woman pregnant and/or nursing Women child bear potential must negative urine pregnancy test . History seizure Taking medication interact haloperidol Subjects significant cardiovascular ( cardiac conduction deficit ) , gastrointestinal , hematologic , neurologic , renal , hepatic pulmonary disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Nausea</keyword>
	<keyword>vomit</keyword>
	<keyword>gastrointestinal symptom</keyword>
	<keyword>palliative care</keyword>
</DOC>